NCT01272908View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 18, 2006

Primary Completion Date

March 12, 2009

Study Completion Date

March 12, 2009

Conditions
Rheumatoid Arthritis
Interventions
DRUG

rituximab

1000 mg intravenously on Days 1 and 15

Trial Locations (41)

18288

Stockholm

20502

Malmo

31392

Oskarström

37185

Karlskrona

39185

Kalmar

41345

Gothenburg

50182

Borås

54185

Skövde

79182

Falun

85186

Sundsvall

97180

Luleå

T5M 0H4

Edmonton

T6G 2B7

Edmonton

V1Y 3G8

Kelowna

V5Z 3Y1

Vancouver

V8V 3P9

Victoria

R3A 1M4

Winnipeg

A1A 5E8

St. John's

A1C 5B8

St. John's

L8N 1Y2

Hamilton

L8S 4J9

Hamilton

L5M 2V8

Mississauga

K2G 6E2

Nepean

K1H 8L6

Ottawa

K1S 1C2

Ottawa

P7B 5G3

Thunder Bay

M4K 1N2

Toronto

M5G 1X5

Toronto

M5T 2S8

Toronto

N8X 5A6

Windsor

H7G 2E6

Laval

H1T 2M4

Montreal

H2L 1S6

Montreal

H2L 4M1

Montreal

H3T 1E2

Montreal

G1V 3M7

Québec

J7P 4J2

Saint-Eustache

G1W 4R4

Sainte-Foy

J1H 5N4

Sherbrooke

G8Z 1Y2

Trois-Rivières

551 85

Jönköping

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01272908 - A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET) | Biotech Hunter | Biotech Hunter